The role of base and prime editing in therapeutics
Interviewee/Contributor
Jonathan Frampton
Organisation
Horizon Discovery Group Plc
Regenerative medicine (Stem cells)
Gene-edited therapies produce first clinical data
Interviewee/Contributor
Janet Lambert
Organisation
Alliance for Regenerative Medicine
Gene and cell therapy as a new pillar of medicine
Interviewee/Contributor
Miguel Forte
Organisation
Bone Therapeutics SA
Advanced therapy financing events in Q1 2019
Interviewee/Contributor
Victoria English
Organisation
MedNous
What ATMP developers need to know about quality
Interviewee/Contributor
Houria Bachtarzi
Organisation
ERA Consulting (UK) Ltd
Building capacity in Europe for cell and gene therapy
Interviewee/Contributor
Yasmin de Faria Krim
Organisation
Independent regulatory affairs professional
Record equity financing in 2018 for ATMPs
Interviewee/Contributor
William Ellington
Organisation
MedNous
A small molecule approach to regenerative medicine
Interviewee/Contributor
Angela Russell and Michael Stein
Organisation
OxStem Ltd
Cell therapy success and the competition for value
Interviewee/Contributor
Miguel Forte
Organisation
Zelluna Immunotherapy AS
Regulatory challenges for cell therapy manufacture
Interviewee/Contributor
Adeyemi Afuwape and Tim Farries
Organisation
ERA Consulting (UK) Ltd